Amicus Therapeutics filings document the former public company’s rare-disease biotechnology business, common stock registration, operating results, governance matters, shareholder voting disclosures, material agreements, risk factors, clinical or regulatory updates, and capital-structure information. The filing record includes Form 8-K reports for quarterly results, corporate updates, and material events tied to its business and securities.
Later filings document Amicus Therapeutics’ completed merger, its survival as a wholly owned subsidiary of BioMarin Pharmaceutical Inc., the removal of its common stock from Nasdaq listing through Form 25, and the termination or suspension of Exchange Act reporting obligations through Form 15. These documents record the company’s transition from a Nasdaq-listed issuer to a subsidiary within BioMarin.
Amicus Therapeutics, Inc. notified Nasdaq of the removal of its Common Stock from listing and registration on the Nasdaq Stock Market. The filing states the Exchange "struck the class of securities from listing" and that the issuer complied with rules "governing the voluntary withdrawal".
Amicus Therapeutics, Inc. reports that the French Ministry of Economics and Finance granted clearance on April 23, 2026 for its planned merger with BioMarin Pharmaceutical under French foreign direct investment screening rules. This clearance satisfies the final outstanding regulatory condition to the merger, aside from items customarily completed at closing.
The merger, under which Amicus will become a wholly owned subsidiary of BioMarin, is now expected to close on April 27, 2026, subject to those remaining closing conditions. The company also reiterates that statements about the expected timing of completion are forward-looking and subject to various risks and uncertainties.